Assessment of baseline HIV viral load as a risk factor for loss of virologic suppression in protease inhibitor-based monotherapy trials

J Acquir Immune Defic Syndr. 2010 Apr;53(5):669; author reply 670. doi: 10.1097/QAI.0b013e3181befc0a.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • HIV / immunology*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Protease Inhibitors / pharmacology*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • RNA, Viral / blood

Substances

  • HIV Protease Inhibitors
  • RNA, Viral